Imcera
This article was originally published in The Gray Sheet
Executive Summary
Chemical, animal and human health products manufacturer expects to take a "significant restructuring charge" in the fourth quarter ending in June. The Northbrook, Illinois-based company plans "major, discrete actions to improve and sustain future earnings prospects and profitability, the greatest part of which...will relate to Pitman-Moore," the group's ailing animal health care unit, according to a March 9 press release. As a result of lackluster performance of its Pitman-Moore and Mallinckrodt Specialty Chemicals units, Imcera anticipates that earnings per share for the third quarter ending March 31 will be "several cents below" the 42 cents from continuing operations in the same period last year. For FY 1993, the firm expects earnings per share to be "only slightly above" the $1.65 reported in 1992, excluding the planned restructuring charge. In December, Imcera announced a management shift tied to Pitman-Moore's lagging performance ("The Gray Sheet" Dec. 14, p. 32).
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.